proguanil hydrochloride.txt

CLINICAL USE

Malaria chemoprophylaxis

DOSE IN NORMAL RENAL FUNCTION

200 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :290.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :75

%Excreted unchanged in urine &nbsp &nbsp : 60

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :20

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20–60 100 mg daily

10 to 20 &nbsp &nbsp : 50 mg every 48 hours

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50 mg weekly

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anticoagulants: effect of warfarin possibly enhanced

Antimalarials: avoid concomitant use with artemether/lumefantrine; increased antifolate effect with pyrimethamine

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Rare reports of haematological changes (e.g. megaloblastic anaemia and pancytopenia) in patients with severe renal impairment

Tags: post-by-auto-php